Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.

Alzheimer's disease CSF PET amyloid-β p-tau plasma tau

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
Nov 2023
Historique:
revised: 19 01 2023
received: 01 11 2022
accepted: 20 01 2023
pmc-release: 20 10 2024
pubmed: 20 4 2023
medline: 20 4 2023
entrez: 20 04 2023
Statut: ppublish

Résumé

Plasma biomarkers are promising tools for Alzheimer's disease (AD) diagnosis, but comparisons with more established biomarkers are needed. We assessed the diagnostic performance of p-tau Plasma p-tau biomarkers had lower dynamic ranges and effect sizes compared to CSF p-tau. Plasma p-tau Plasma and CSF p-tau p-tau

Identifiants

DOI: 10.1002/alz.13026 PMID: 37078495 PMC: PMC10587362
pubmed: 37078495
doi: 10.1002/alz.13026
pmc: PMC10587362
mid: NIHMS1882773
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4967-4977

Subventions

Organisme : NIA NIH HHS
ID : R01 AG068398
Pays : United States
Organisme : Alzheimer's Association
ID : NIRG-12-92090
Pays : United States
Organisme : Alzheimer's Association
ID : NIRP-12-259245
Pays : United States
Organisme : Alzheimer's Association
ID : SG-23-1038904 QC
Pays : United States

Informations de copyright

© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Références

Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266-273. doi: 10.1097/NEN.0b013e31824b211b
Therriault J, Pascoal TA, Benedet AL, et al. Frequency of biologically-defined AD in relation to age, sex, APOEε4 and cognitive impairment. Neurology. 2021;96:e975-e985.
Kostopoulou O, Delaney BC, Munro CW. Diagnostic difficulty and error in primary care - A systematic review. Fam Pract. 2008;25:400-413. doi: 10.1093/fampra/cmn071
Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare Beneficiaries with Mild Cognitive Impairment or Dementia. JAMA. 2019;321:1286-1294. doi: 10.1001/jama.2019.2000
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691-1704. doi: 10.1056/nejmoa2100708
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of Aducanumab in early Alzheimer's disease. J Prev Alzheimer's Dis. 2022;9:197-210.
Cummings JL, Aisen PS, Apostolova LG, Atri A, Salloway S, Weiner MW. Aducanumab: appropriate use recommendations. J Prev Alzheimer's Dis. 2021;8:398-410. doi: 10.14283/jpad.2021.45
Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387-397. doi: 10.1038/s41591-020-0762-2
Janelidze S, Mattsson N, Palmqvist S, et al. Plasma p-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020;26:379-386. doi: 10.1038/s41591-020-0755-1
Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimer's Dement. 2018;14:989-997. doi: 10.1016/j.jalz.2018.02.013
Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422-433. doi: 10.1016/S1474-4422(20)30071-5
Janelidze S, Berron D, Smith R, et al. Associations of plasma Phospho-Tau217 levels with Tau Positron Emission Tomography in early Alzheimer disease. JAMA Neurol. 2021;78:149-156. doi: 10.1001/jamaneurol.2020.4201
Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021;141:709-724. doi: 10.1007/s00401-021-02275-6
Milà-Alomà M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer's disease. Nat Med. 2022;28:1797-1801. doi: 10.1038/s41591-022-01925-w
Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021;20:739-752. doi: 10.1016/S1474-4422(21)00214-3
Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772-781. doi: 10.1001/jama.2020.12134
Therriault J, Vermeiren M, Servaes S, et al. Association of phosphorylated tau biomarkers with amyloid-PET vs with tau-PET. JAMA Neurol. 2023;80:188-199.
Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020;217:1-12. doi: 10.1084/JEM.20200861
Karikari TK, Ashton NJ, Brinkmalm G, et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18. doi: 10.1038/s41582-022-00665-2
Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954-963. doi: 10.1038/s41591-021-01382-x
Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21:66-77. doi: 10.1016/S1474-4422(21)00361-6
Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022:1-18. doi: 10.1002/alz.12756
Therriault J, Benedet AL, Pascoal TA, et al. Association of Apolipoprotein e ϵ4 with Medial Temporal Tau Independent of Amyloid-β. JAMA Neurol. 2020;77:470-479. doi: 10.1001/jamaneurol.2019.4421
Therriault J, Pascoal TA, Lussier FZ, et al. Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nat Aging. 2022;2:526-535. doi: 10.1038/s43587-022-00204-0
Karikari TK, Emeršič A, Vrillon A, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimer's Dement. 2021;17:755-767. doi: 10.1002/alz.12236
Ashton NJ, Benedet AL, Pascoal TA, et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. EBioMedicine. 2022;76:103836. doi: 10.1016/j.ebiom.2022.103836
Therriault J, Benedet AL, Pascoal TA, et al. Association of plasma p-tau181 with memory decline in non-demented adults. Brain Commun. 2021;3:1-10. doi: 10.1093/braincomms/fcab136
Triana-Baltzer G, Moughadam S, Slemmon R, et al. Development and validation of a high-sensitivity assay for measuring p217+tau in plasma. Alzheimer's Dement Diagnosis. Assess Dis Monit. 2021;13:1-14. doi: 10.1002/dad2.12204
Doré V, Doecke JD, Saad ZS, et al. Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alzheimer's dement diagnosis. Assess Dis Monit. 2022;14:1-11. doi: 10.1002/dad2.12307
Servaes S, Lussier FZ, Therriault J, et al. pTau heterogeneity as a measure for disease severity in incipient Alzheimer's disease. Alzheimer's Dement. 2022;18:e063749.
Tissot C, Therriault J, Kunach P, et al. Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET. EBioMedicine. 2022;76:1-13. doi: 10.1016/j.ebiom.2022.103837
Therriault J, Benedet AL, Pascoal TA, et al. Determining amyloid-β positivity using 18F-AZD4694 PET imaging. J Nucl Med. 2021;62:247-252. doi: 10.2967/jnumed.120.245209
Pascoal TA, Therriault J, Benedet AL, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143:2818-2830. doi: 10.1093/brain/awaa180
Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's Dement. 2017;13:205-216. doi: 10.1016/j.jalz.2016.08.005
Therriault J, Pascoal TA, Savard M, et al. Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer's disease. Sci Transl Med. 2022;14:eabc8693. doi: 10.1002/alz.044897
Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimer's Dement. 2018;14:535-562. doi: 10.1016/j.jalz.2018.02.018
Knopman DS, Amieva H, Petersen RC, et al. Alzheimer disease. Nat Rev Dis Prim. 2021;7:1-21. doi: 10.1038/s41572-021-00269-y
Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413-446. doi: 10.1016/S0140-6736(20)30367-6
Therriault J, Zimmer ER, Benedet AL, Pascoal TA, Gauthier S, Rosa-neto P. Staging of Alzheimer's disease : past, present, and future perspectives. Trends Mol Med. 2022:1-16. doi: 10.1016/j.molmed.2022.05.008
Therriault J, Pascoal TA, Savard M, et al. Topographical distribution of amyloid-β, tau and atrophy in behavioral /dysexecutive AD patients. Neurology. 2020;96:e81-92. doi: 10.1212/WNL.0000000000011081
Moscoso A, Karikari TK, Grothe MJ, et al. CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: implications for clinical trial design. Alzheimer's Dement. 2022:1-13. doi: 10.1002/alz.12570
Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet. 2002;359:881-884. doi: 10.1016/S0140-6736(02)07948-5
Groot C, Cicognola C, Bali D, et al. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer's. Res Ther. 2022;14:1-12. doi: 10.1186/s13195-022-01005-8
Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain. 2022:1-6.
Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-Head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375-1382. doi: 10.1001/jamaneurol.2021.3180
Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28:1398-1405. Aiailable at https://www.nature.com/articles/s41591-022-01822-2. doi: 10.1038/s41591-022-01822-2
Benedet AL, Brum WS, Hansson O, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's. Res Ther. 2022;14:1-11. doi: 10.1186/s13195-021-00942-0
Sackett D. Superiority trials, non-inferiority trials, and prisoners of the 2-sided null hypothesis. BMJ Evidence-Based Med. 2004;9:100-100. doi: 10.1136/ebm.9.4.100
Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. Jama. 2006;295:1172-1174. doi: 10.1001/jama.295.10.1172
Lui KJ, Zhou XH. Testing non-inferiority (and equivalence) between two diagnostic procedures in paired-sample ordinal data. Stat Med. 2004;23:545-559. doi: 10.1002/sim.1607
Schindler SE, Karikari TK. Comorbidities confound Alzheimer's blood tests. Nat Med. 2022:1-2. doi: 10.1038/s41591-022-01875-3
Schindler SE, Karikari TK, Ashton NJ, et al. Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light. Neurology. 2022;99:E245-E257. doi: 10.1212/WNL.0000000000200358

Auteurs

Joseph Therriault (J)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Stijn Servaes (S)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Cécile Tissot (C)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.

Nesrine Rahmouni (N)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.

Nicholas J Ashton (NJ)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Wallenberg Centre for Molecular Medicine, University of Gothenburg, Gothenburg, Sweden.
King's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Institute Clinical Neuroscience Institute, London, UK.
NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.

Andréa Lessa Benedet (AL)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.

Thomas K Karikari (TK)

Wallenberg Centre for Molecular Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA.

Arthur C Macedo (AC)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Firoza Z Lussier (FZ)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA.

Jenna Stevenson (J)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.

Yi-Ting Wang (YT)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Jaime Fernandez-Arias (J)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Alyssa Stevenson (A)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.

Kely Quispialaya Socualaya (KQ)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Arlette Haeger (A)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Tahnia Nazneen (T)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Étienne Aumont (É)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Ali Hosseini (A)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Soham Rej (S)

Department of Psychiatry, McGill University Montreal, Montreal, Quebec, Canada.

Paolo Vitali (P)

Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Gallen Triana-Baltzer (G)

Neuroscience Biomarkers, Janssen Research & Development, La Jolla, California, USA.

Hartmuth C Kolb (HC)

Neuroscience Biomarkers, Janssen Research & Development, La Jolla, California, USA.

Jean-Paul Soucy (JP)

Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Tharick A Pascoal (TA)

Department of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA.

Serge Gauthier (S)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK.
UK Dementia Research Institute at UCL, London, UK.
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.

Kaj Blennow (K)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

Pedro Rosa-Neto (P)

Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal, Montréal, Québec, Canada.
Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
ORCID: 0000-0001-9116-1376

Classifications MeSH